EFTA Document EFTA01457561

11 May 2016 Pharmaceuticals GlaxoSmithKline Performance review charts 'Figure 6: Quarterly and annual Core EPS growth (CER, %) 15 10 - 5 - 0 -to - -15 - 9 9 7 I 01 2 ; 4 .5 - -g -11 Ca N NCI CV IV e) 9R2g92289Rg99 -12 el Ir O LT LS -18 • - .3 .2 4 - N Cl 0 )- )- )- )- Li. LL LL LL Sane 0•4.0d0 ant aneenynil• Figure 7: Pharma CER growth rates 10% 5% , 0% -10% •15% 8% 2% -1% 2% -3% -3% 4% -3% -316 .4% -5% 4% • 3 94 NCVNNnelne100000